Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Health
Joseph James

AbbVie's Once-Daily Parkinson's Pill Juvmo Wins FDA Approval, with Nausea, Dizziness, and Headache Common in Trials

The FDA on Sept. 25 approved Juvmo (tavapadon), a once-daily pill from AbbVie, to treat Parkinson's disease in adults, according to the agency's 2026 list of novel drug approvals. Nausea, dizziness, and headache were among the most common side effects reported in clinical trials.

AbbVie did not disclose a price or launch date, Reuters reported. According to the same report, Citi analysts had expected a third-quarter 2026 launch, with gradual uptake as Medicare coverage is negotiated.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.